MiraLAX Targeted In Petition To FDA, But Physicians Back Pediatric Use
This article was originally published in The Tan Sheet
Executive Summary
A consumer group petitions FDA for a black box warning on Merck’s MiraLAX and generic equivalents, citing the potential for adverse reactions in children. Gastroenterologists largely have not seen such risks from off-label pediatric use of the OTC laxative.
You may also be interested in...
Laxative Ingredient Pediatric Study Provides Compass For FDA Action
FDA supports research to evaluate long-term exposure of polyethylene glycol 3350 in children, saying “pharmacokinetic data from pediatric patients would provide better information” on the ingredient’s safety. A consumer group that petitioned FDA for a black box warning has additional questions.
Laxative Ingredient Pediatric Study Provides Compass For FDA Action
FDA supports research to evaluate long-term exposure of polyethylene glycol 3350 in children, saying “pharmacokinetic data from pediatric patients would provide better information” on the ingredient’s safety. A consumer group that petitioned FDA for a black box warning has additional questions.
Metoclopramide Gets Boxed Warning, REMS, For Movement Disorder Risk
FDA issued a class-wide requirement Feb. 26 for metoclopramide-containing products to gain a boxed warning and Risk Evaluation and Mitigation Strategy to address the gastrointestinal drug's associated risk of tardive dyskinesia